HLN
Haleon plcNYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$44.03B
P/E Ratio
20.16
EPS
$0.49
Beta
0.33
52W High
$11.35
52W Low
$8.71
50-Day MA
$10.48
200-Day MA
$9.86
Dividend Yield
0.72%
Profit Margin
15.10%
Forward P/E
19.05
PEG Ratio
2.64
About Haleon plc
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Fundamentals
| Revenue (TTM) | $11.03B |
| Gross Profit (TTM) | $7.14B |
| EBITDA | $2.74B |
| Operating Margin | 23.20% |
| Return on Equity | 10.30% |
| Return on Assets | 4.67% |
| Revenue/Share (TTM) | $2.46 |
| Book Value | $2.44 |
| Price-to-Book | 2.04 |
| Price-to-Sales (TTM) | 3.99 |
| EV/Revenue | 3.679 |
| EV/EBITDA | 14.19 |
| Quarterly Earnings Growth (YoY) | 92.00% |
| Quarterly Revenue Growth (YoY) | 0.60% |
| Shares Outstanding | $4.46B |
| Float | $8.86B |
| % Insiders | 0.01% |
| % Institutions | 12.70% |
Analyst Ratings
Consensus ($12.07 target)
2
Strong Buy1
Buy1
HoldData last updated: 4/8/2026